Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription


2 BMC Cancer
2 BMC Urol
1 Br J Cancer
1 Curr Treat Options Oncol
1 Eur Urol
1 Hum Pathol
1 Int J Oncol
5 Int J Urol
2 J Clin Oncol
1 J Magn Reson Imaging
3 J Natl Cancer Inst
1 J Nucl Med
4 J Urol
1 Magn Reson Imaging
1 PLoS One
1 Prostate

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Cancer

  1. ENKE JS, Gross M, Grosser B, Sipos E, et al
    SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
    BMC Cancer. 2024;24:65.
    PubMed         Abstract available

  2. MULATI Y, Lai C, Luo J, Hu J, et al
    Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer.
    BMC Cancer. 2024;24:44.
    PubMed         Abstract available

    BMC Urol

  3. PANKEN E, Frydenlund N, Mistry N, Prabhu R, et al
    Heteronormative biases and distinctive experiences with prostate cancer among men who have sex with men: a qualitative focus group study.
    BMC Urol. 2024;24:10.
    PubMed         Abstract available

  4. ZHANGHUANG C, Zhu J, Li Y, Wang J, et al
    Prognostic significance of surgery and radiotherapy in elderly patients with localized prostate cancer: establishing and time-based external validation a nomogram from SEER-based study.
    BMC Urol. 2024;24:12.
    PubMed         Abstract available

    Br J Cancer

  5. MAH CY, Nguyen ADT, Niijima T, Helm M, et al
    Peroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.
    Br J Cancer. 2024 Jan 12. doi: 10.1038/s41416-023-02557.
    PubMed         Abstract available

    Curr Treat Options Oncol

  6. FANG AM, Jackson J, Gregg JR, Chery L, et al
    Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer.
    Curr Treat Options Oncol. 2024 Jan 3. doi: 10.1007/s11864-023-01162.
    PubMed         Abstract available

    Eur Urol

  7. CHI KN, Armstrong AJ, Krause BJ, Herrmann K, et al
    Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2024 Jan 6:S0302-2838(23)03297-9. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available

    Hum Pathol

  8. BACHERT SE, Di J, Zhang S, Short HE, et al
    TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
    Hum Pathol. 2024;143:42-49.
    PubMed         Abstract available

    Int J Oncol

  9. ZHONG K, Luo W, Li N, Tan X, et al
    CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
    Int J Oncol. 2024;64:20.
    PubMed         Abstract available

    Int J Urol

  10. HATANO K
    Editorial Comment on "Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea".
    Int J Urol. 2024 Jan 12. doi: 10.1111/iju.15393.

    Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.

  12. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
    Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
    PubMed         Abstract available

  13. OKIHARA K, Ueda T, Fujihara A, Shiraishi T, et al
    Novel image-guided marker aimed at organ-preserving therapies for prostate cancer.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15389.
    PubMed         Abstract available

  14. OKANO K, Miyai K, Mikoshi A, Edo H, et al
    Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15385.
    PubMed         Abstract available

    J Clin Oncol

  15. HALABI S, Roy A, Rydzewska L, Guo S, et al
    Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2301535. doi: 10.1200/JCO.23.01535.
    PubMed         Abstract available

    Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2302310. doi: 10.1200/JCO.23.02310.

    J Magn Reson Imaging

    Editorial for "Association of Pathological Features and Multiparametric MRI-Based Radiomics with TP53-Mutated Prostate Cancer".
    J Magn Reson Imaging. 2024 Jan 8. doi: 10.1002/jmri.29224.

    J Natl Cancer Inst

  18. FEDELI U, Barbiellini Amidei C, Han X, Jemal A, et al
    Changes in cancer-related mortality during the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2024;116:167-169.
    PubMed         Abstract available

  19. WILKINSON S, Sowalsky AG
    Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.
    J Natl Cancer Inst. 2024;116:12-14.

  20. LEE KM, Nelson T, Bryant A, Teerlink C, et al
    Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
    J Natl Cancer Inst. 2024 Jan 11:djae002. doi: 10.1093.
    PubMed         Abstract available

    J Nucl Med

  21. LIGHT A, Lazic S, Houghton K, Bayne M, et al
    Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
    PubMed         Abstract available

    J Urol

  22. GARNICK MB, Hafron J, Crawford ED
    Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2024 Jan 5:101097JU0000000000003831. doi: 10.1097/JU.0000000000003831.

  23. ESCOBAR AJ, Krishna S, Flowers KM, Abello A, et al
    Practical Use of Self-Adjusted Nitrous Oxide During Transrectal Prostate Biopsy: A Double-Blind Randomized Controlled Trial.
    J Urol. 2024;211:214-222.
    PubMed         Abstract available

  24. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:205-213.
    PubMed         Abstract available

  25. MISTRY NA, Sun Z, Sweis J, McCall C, et al
    Development and Validation of a Prostate Biopsy Risk Calculator in Black Men.
    J Urol. 2024;211:223-233.
    PubMed         Abstract available

    Magn Reson Imaging

  26. XINYANG S, Shuang Z, Tianci S, Xiangyu H, et al
    A machine learning radiomics model based on bpMRI to predict bone metastasis in newly diagnosed prostate cancer patients.
    Magn Reson Imaging. 2024;107:15-23.
    PubMed         Abstract available

    PLoS One

  27. Retraction: Potent Anti-Proliferative, Pro-Apoptotic Activity of the Maytenus Royleanus Extract against Prostate Cancer Cells: Evidence in In-Vitro and In-Vivo Models.
    PLoS One. 2024;19:e0297383.


  28. PANACH-NAVARRETE J, Gonzalez-Marrachelli V, Morales-Tatay JM, Garcia-Morata F, et al
    Metabolic analysis using HR-MAS in prostate tissue for prostate cancer diagnosis.
    Prostate. 2024 Jan 11. doi: 10.1002/pros.24670.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.